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Abstract
Background: Hodgkin lymphoma (HL) survivors are at increased risk for developing valvular heart disease (VHD). We 
evaluated the determinants of the risk and the radiation dose-response.
Methods: A case-control study was nested in a cohort of 1852 five-year HL survivors diagnosed at ages 15 to 41 years 
and treated between 1965 and 1995. Case patients had VHD of at least moderate severity as their first cardiovascular 
diagnosis following HL treatment. Control patients were matched to case patients for age, gender, and HL diagnosis 
date. Treatment and follow-up data were abstracted from medical records. Radiation doses to heart valves were 
estimated by reconstruction of individual treatments on representative computed tomography datasets. All statistical 
tests were two-sided.
Results: Eighty-nine case patients with VHD were identified (66 severe or life-threatening) and 200 control patients. 
Aortic (n = 63) and mitral valves (n = 42) were most frequently affected. Risks increased more than linearly with 
radiation dose. For doses to the affected valve(s) of less than or equal to 30, 31–35, 36–40, and more than 40 Gy, VHD 
rates increased by factors of 1.4, 3.1, 5.4, and 11.8, respectively (Ptrend < .001). Approximate 30-year cumulative risks 
were 3.0%, 6.4%, 9.3%, and 12.4% for the same dose categories. VHD rate increased with splenectomy by a factor of 2.3 
(P = .02).
Conclusions: Radiation dose to the heart valves can increase the risk for clinically significant VHD, especially at doses 
above 30 Gy. However, for patients with mediastinal involvement treated today with 20 or 30 Gy, the 30-year risk will be 
increased by only about 1.4%. These findings may be useful for patients and doctors both before treatment and during 
follow-up.
Hodgkin lymphoma (HL) is an archetype of curable malig-
nancy. HL treatment has improved over the last 50 years, lead-
ing to a 10-year survival rate of over 80%. However, it is well 
documented that radiotherapy (RT), as given in the past for 
HL, is an important cause of increased cardiovascular mor-
tality and morbidity in long-term survivors (1–8). Increased 
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recognition of this risk and combination treatment including 
both chemotherapy and RT has led to a reduction in doses and 
volumes of RT used for HL (9). Nevertheless, RT may still result 
in substantial incidental cardiac exposure if the disease affects 
the mediastinum (10). Thus, whilst it is thought that the risk of 
radiation-related heart disease is now lower than for patients 
treated in the past, the magnitude of the risk for HL patients 
treated today is unknown.
Recent studies in breast cancer patients have demon-
strated a dose-response relationship for radiation-related 
ischaemic heart disease (11). Valvular heart disease (VHD) is 
also increased following cardiac irradiation (2,8,12–14). Recent 
screening studies in HL survivors have reported that 32% of 
those given mediastinal irradiation developed asymptomatic 
valvular defects after six years (15), whilst at 20  years 42% 
had imaging evidence of valvular dysfunction (16). The dose-
response relationship for radiation-related VHD is, however, 
still unknown, and there have been few studies of other risk 
factors for VHD. The aims of this study were, therefore, to esti-
mate the dose-response relationship for radiation-related VHD 
and to evaluate other possible determinants of VHD risk in 
order to assess risk for patients whose treatment involves inci-
dental irradiation of the heart.
Methods
Study Population
A cohort of 1852 five-year survivors of HL treated between 1965 
and 1995 was identified through hospital-based cancer regis-
tries at The Netherlands Cancer Institute, Amsterdam (NKI-
AVL), The Erasmus MC-Daniel den Hoed Cancer Center (DdHK), 
Rotterdam, and Leiden University Medical Center (LUMC). 
Details are given elsewhere (1–3,17,18). Patients were included 
if they: 1) had a histologically confirmed diagnosis of HL when 
age 15 to 41 years, 2) had no other malignancy (except nonmela-
noma skin cancer or carcinoma in situ of breast or cervix) prior 
to HL, and 3)  survived five or more years after HL diagnosis. 
Follow-up was 98% complete as of January 1, 2002; 54% were fol-
lowed to 2005 or later.
For the present study, cohort members diagnosed with VHD 
were identified initially from their hospital records or a postal 
questionnaire completed by their general practitioner. Case 
patients were individuals subsequently confirmed by further 
correspondence with their general practitioner and/or cardiolo-
gist to have at least moderately severe VHD (defined by Common 
Terminology Criteria for Adverse Events [CTCAE] version 4.0, 
grade ≥2 [19]) as their first diagnosis of clinically significant 
heart disease after HL diagnosis.
For each case with VHD, three control patients were 
selected from cohort members, matched on sex, age at HL 
diagnosis (≤1  year), and date of HL diagnosis (≤3  years). 
Control patients were free of any cardiac disease of grade 
2 or higher on a cutoff date, defined as the date of HL diag-
nosis plus a time interval equal to the interval from the 
date of HL diagnosis to the date of VHD diagnosis for the 
matched case. If fewer than two control patients were found 
for a case, the matching criteria were relaxed until two were 
found, up to a maximum difference of four years for age at 
HL diagnosis and five years for date of diagnosis. Control 
patients were selected with replacement, so some individu-
als were a control patient for more than one case patient. 
The study protocol was approved by the ethics review board 
of the NKI-AVL.
Data Collection
Details of medical history, HL treatment at diagnosis, and any relapse, 
cumulative doses of cytotoxic drugs, second malignancies, cardio-
vascular diseases, and cardiovascular risk factors both at diagnosis 
of HL and at diagnosis of VHD (index date for control patients) were 
abstracted from medical records for case patients and two control 
patients. Where data had already been abstracted for a third matched 
control patient for use in other studies, this was also included.
Copies of original RT prescription sheets and planning and 
verification x-rays were obtained. Where original prescriptions 
were unavailable, information about RT including dates, ana-
tomical areas, dose, fractionation, and treatment energy were 
abstracted from clinical notes.
Retrospective Radiation Dosimetry Methods
RT regimens were reconstructed using the Eclipse treatment 
planning system (Version 10.0.28, Varian Medical System, Palo 
Alto, CA). Two substitute computed tomography (CT) dataset 
(for men and women, respectively) were chosen from a library 
of 50 to be representative regarding anatomy and estimated 
heart dose from a standardized mantle field. Heart and heart 
valves were outlined as per published guidelines (20). Treatment 
fields, shielding, prescription points and delivered doses were 
reproduced from original RT prescriptions and planning x-rays 
(Figure  1). Dose distributions were calculated using the aniso-
tropic analytic algorithm for megavoltage (MV) treatments and 
the pencil beam algorithm for cobalt-60 treatments. To simu-
late the original prescription, dose distributions were calculated 
initially with the homogeneity correction inactivated to assess 
delivered dose and then recalculated with the correction reacti-
vated to estimate dose distribution more accurately. Doses were 
converted to equivalent dose in 2 Gray (Gy) fractions (EQD2) (21) 
calculated from dose volume histograms, assuming an alpha-
beta ratio of two for late cardiac effects (22). When fraction size 
varied during treatment, EQD2 was calculated separately for each 
fraction size and then summed. Doses were estimated for the 
affected valve for case patients and the corresponding valve for 
control patients. There was only trivial variation in dose across a 
valve, therefore mean valvular dose was used for analyses.
Statistical Analysis
Cumulative risk of VHD in the cohort was calculated treating 
patients as censored when they developed another heart disease 
and death as a competing risk. Ninety-five percent confidence 
intervals (CIs) for cumulative risk were derived using the delta 
method (23). Incidence rate ratios (RRs) for VHD for different lev-
els of each factor were calculated using logistic regression con-
ditional on sets of individual case patients and their matched 
control patients. Ninety-five percent confidence intervals for fac-
tors with two levels used the Wald method. Ninety-five percent 
confidence intervals for factors with two or more levels used the 
amount of information in each category, including the reference 
category (24). The dose-response was estimated by modelling 
VHD rate as Κm(1+βd), where d is dose to the valve of an individual 
patient, Κm is a constant specific to each matched set, and β is 
the proportional increase in VHD rate per unit increase in dose. 
Nonlinearity was evaluated by including an exponential term: 
Κm[1+βd.exp(δd)] and goodness of fit assessed by likelihood ratio 
test. Multiple regression was used to control for confounding and 
to assess interactions between radiation dose and other factors. 
Approximate cumulative risks of VHD for categories of radiation 
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dose were estimated from the VHD rate ratios together with the 
cumulative risk of VHD for the entire cohort, assuming that the 
distribution of all individuals in the cohort across the dose catego-
ries was equal to that for the control patients. Ninety-five percent 
confidence intervals were calculated from the profile-likelihood. 
Statistical tests were two-sided, and P values of less than or equal 
to .05 were considered stastically significant. Analyses were per-
formed using STATA statistical software version 11.0 (STATAcorp 
2009) (25) and Epicure version 1.8 (Hirosoft International) (26).
Results
General
The cohort of 1852 five-year HL survivors was followed for a 
median of 18.8 years (interquartile range = 13.1–25.6). Eighty-three-
point-three percent received mediastinal RT. A total of 89 patients 
had VHD of at least moderate severity as their first cardiovascu-
lar diagnosis, most commonly affecting the aortic (n = 63) and/or 
mitral (n = 42) valves (Table 1). The median interval between HL 
diagnosis and VHD diagnosis was 23.3 years, and at 30 years after 
HL diagnosis the cumulative risk of VHD was 8.0% (95% CI = 6.2% 
to 10.0%) (Figure 2). The median follow-up after VHD diagnosis was 
7.6 years, during which time 56% progressed in grade of severity. 
Twenty-two of the 89 case patients died from cardiac causes and 
a further 17 from other causes. Two hundred control patients 
were included in the case-control study (Table 2), and the length 
of follow-up was virtually identical for case patients and control 
patients (Supplementary Table 1, available online).
Patient-Related Risk Factors
The total number of cardiovascular risk factors recorded was 
associated with an increased VHD rate (Ptrend  =  .002) (Table  3). 
When the risk factors were considered individually, obesity at 
HL diagnosis (RR = 2.1, 95% CI = 1.1 to 3.8, P = .02), hypertension 
at end of follow-up (RR = 2.0, 95% CI = 1.1 to 3.5, P =  .02), and 
hypercholesterolaemia at end of follow-up (RR = 4.9, 95% CI = 2.6 
to 9.1, P < .001) were associated with an increase in VHD. When 
these factors were considered simultaneously, the associations 
with obesity at HL diagnosis and hypercholesterolaemia at end 
of follow-up changed little in magnitude and remained statisti-
cally significant, but the association with hypertension at end 
of follow-up was smaller and no longer statistically significant.
Radiation Dose
The VHD rate was more closely related to the dose to the 
affected valve (Ptrend < .001) than to the prescribed mediastinal 
dose (Ptrend =  .003) (Table 4). The average of the mean doses to 
the affected heart valve in case patients was 37.0 Gy (SD = 9.2), 
compared with only 30.7 Gy (SD  =  13.8) for control patients 
(Pdifference  =  .001). For doses to the affected valve(s) of less than 
or equal to 30, 31–35, 36–40, and more than 40 Gy, VHD rates 
increased by factors of 1.4, 3.1, 5.4, and 11.8, respectively. There 
were larger percentages of control patients than case patients 
in dose categories 0, up to 10, 10–19, 20–30, and 31–35 Gy and 
larger percentages of case patients than control patients in cat-
egories 36–40 and more than 40 Gy (Supplementary Figure  1, 
available online). The dose-response relationship was nonlin-
ear (Pnonlinearity = .03) (Figure 3). For doses to the affected valve of 
less than or equal to 30 Gy, the VHD rate increased by only 2.5% 
(95% CI = -2.2% to 29.2%) per Gy, but it increased by 6.5% (95% 
CI = -0.2% to 42.3%), 11.2% (95% CI = 1.8% to 59.8%), and 24.3% 
(95% CI = 4.6% to 139.5%) per Gy, respectively, for doses of 31–35 
Gy, 36–40 Gy, and more than 40 Gy. Approximate 30-year cumu-
lative risks of VHD were 1.6%, 3.0%, 6.4%, 9.3%, and 12.4% for 
individuals with radiation doses of 0, less than or equal to 30, 
31–35, 36–40, and more than 40 Gy to the affected valve, respec-
tively (Figure 4).
Figure 1. An example of an original simulation film used during the 1960s to 1990s to plan radiotherapy for Hodgkin lymphoma, with field borders marked in black 
(left). The same field has been reconstructed within a modern radiotherapy treatment planning system on a substitute CT dataset with the field overlaid on a digitally 
reconstructed radiograph, with the field borders marked in yellow (right). The heart (pink) and the heart valves (blue) are outlined to demonstrate their position. 
A = aortic valve; M = mitral valve; P = pulmonary valve; T = tricuspid valve.
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Other Treatment-Related Risk Factors
Splenectomy after HL diagnosis was associated with an 
increased VHD rate (RR = 2.3, 95% CI = 1.3 to 4.3, P = .007) (Table 4). 
This association changed little in magnitude and remained sta-
tistically significant after adjusting for radiation dose to the 
affected valve (RR = 2.3, 95% CI = 1.1 to 4.5, P = .02).
VHD rates were reduced in patients given vincristine (RR = 0.4, 
95% CI = 0.2 to 0.7, P = .003) or procarbazine (RR = 0.5, 95% CI = 0.3 
to 0.9, P = .02); the reductions were attenuated and no longer sta-
tistically significant after adjustment for radiation dose to the 
affected valve and splenectomy (Table 4). Other factors, including 
anthracycline chemotherapy (RR = 1.2, 95% CI = 0.3 to 4.3), were 
not statistically significantly associated with VHD.
Modification of the Effect of Radiation by Other 
Factors
The possible modifying effect of other factors on the radiation-
related VHD rate was evaluated by comparing VHD rate ratios for 
Table 1. Characteristics of the cases of valvular heart disease (VHD) recorded as a first cardiac diagnosis, according to the Common Terminol-
ogy Criteria for Adverse Events (CTAE) version 4 (19), treatments given, and status at the end of follow-up
Characteristic Men, No. (%) Women, No. (%) Total patients, No. (%)
First valvular defect
 Aortic 22 (73.3) 23 (39.0) 45 (50.6)
 Mitral 3 (10.0) 19 (32.2) 22 (24.7)
 Aortic + mitral 2 (6.7) 10 (17.0) 12 (13.5)
 Aortic + tricuspid 1 (3.3) 0 (0.0) 1 (1.1)
 Mitral + tricuspid 0 (0.0) 3 (5.1) 3 (3.4)
 Aortic + mitral + tricuspid 1 (3.3) 4 (6.8) 5 (5.6)
 Unknown 1 (3.3) 0 (0.0) 1 (1.1)
Initial CTCAE grade of VHD
 Grade I 6 (20.0) 17 (28.8) 23 (25.8)
 Grade II 16 (53.3) 25 (42.4) 41 (46.1)
 Grade III 5 (20.0) 15 (28.8) 20 (22.5)
 Grade IV 1 (1.1) 2 (2.3) 3 (3.4)
 Unknown 2 (2.3) - 2 (2.3)
Progression of valve defect
 No 13 (43.4) 26 (44.1) 39 (43.8)
 Yes 17 (56.7) 33 (55.9) 50 (56.2)
Highest CTCAE grade of VHD
 Grade II 7 (23.3) 16 (27.1) 23 (25.8)
 Grade III 3 (10.0) 15 (25.4) 18 (20.2)
 Grade IV 20 (66.7) 28 (47.5) 48 (53.9)
Basis for Diagnosis of VHD
 Echocardiography 13 (43.3) 42 (71.2) 55 (61.8)
 Heart catheterisation 4 (13.3) 1 (1.7) 5 (5.6)
 Both of above 5 (16.7) 2 (3.4) 7 (7.9)
 Unknown* 8 (26.7) 14 (23.7) 22 (24.7)
Treatment for VHD
 Drug therapy 3 (10.0) 14 (23.7) 17 (19.1)
 Valve replacement or repair 15 (50.0) 10 (17.0) 25 (28.1)
 Both of above 3 (10.0) 2 (3.4) 5 (5.6)
 None 7 (23.3) 30 (50.9) 37 (41.6)
 Unknown 2 (6.7) 3 (5.1) 5 (5.6)
Status at end of follow-up
 Alive 17 (56.7) 33 (55.9) 50 (56.2)
 Dead of cardiac cause† 8 (26.7) 14 (23.7) 22 (24.7)
 Dead of other cause‡ 5 (16.7) 12 (20.3) 17 (19.1)
Totals 30 (100.0) 59 (100.0) 89 (100.0)
* For these patients 10 had valve replacement or repair, five received drug therapy, five received no treatment, and for two treatments was unknown.
† Congestive heart failure (5), ischaemic heart disease (4), sudden cardiac death (4), valvular heart disease (3), endocarditis (3), other/unspecified cardiac death (3).
‡ Second malignancy (10), other non-neoplastic cause (6), unknown (1).
Figure 2. Cumulative risk of valvular heart disease as (VHD) a first cardiac diag-
nosis among five-year survivors of Hodgkin lymphoma (HL) by years since ini-
tial HL diagnosis. Cumulative risk was calculated treating patients as censored 
when they developed another heart disease and death as a competing risk.
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individuals with radiation dose to the affected valve of greater 
than or equal to 35 Gy to that for individuals with doses of less 
than 35 Gy for different levels of each factor (Supplementary 
Table  2, available online). For individuals treated in calendar 
periods between 1965 and 1974, 1975 and 1984, and 1985 and 
1994, the VHD rate ratios of greater than or equal to 35 Gy vs less 
than 35 Gy were 1.3, 6.0, and 5.7, respectively (Pheterogeneity = .03), but 
no other factors statistically significantly modified the effect of 
radiation. Allowing for the effect of splenectomy had little effect 
on the dose-response relationship in Figure 3 (data not shown).
Discussion
This study provides, for the first time, quantitative estimates of 
the relationship between radiation dose to the heart valves and 
subsequent risk of clinically significant VHD. The relationship is 
nonlinear, with little or no increase following doses below 30 Gy, 
whilst for doses above 30 Gy the percentage increase in the VHD 
rate per Gy increases progressively with increasing dose. This 
study has also provided approximate estimates of 30-year cumu-
lative absolute risks of VHD for categories of radiation dose to the 
heart valves. The current standard radiation dose for Hodgkin 
lymphoma is 20 or 30 Gy. Patients with mediastinal involvement 
whose heart valves are exposed to these doses may expect only 
around 1.4% higher cumulative risk of clinically significant VHD 
after 30 years compared with those treated without RT.
Our study considered only VHD occurring before any other 
diagnosis of heart disease. We did this to avoid confusing the 
direct effect of treatment for HL on VHD, with that occurring as 
a secondary consequence of other heart disease, such as cardiac 
failure and ischaemic heart disease. Our estimates therefore 
underestimate the total incidence of VHD in the cohort, but cor-
rectly estimate that occurring as a direct effect of treatment.
Three recent studies have examined the relationship between 
VHD and RT for HL. Among 1132 HL survivors treated between 
1978 and 1995, VHD was diagnosed in 3% (33 case patients) after 
a median follow-up of 19.5  years (12). Prescribed mediastinal 
radiation dose was the only independent risk factor for VHD. No 
cases of VHD were observed for individuals with doses of 20 Gy, 
while the 25-year cumulative risks among individuals with pre-
scribed doses of 25, 30, and 36 Gy were 2%, 1%, and 16%, respec-
tively. These findings are consistent with those of our own study.
A second study, including 56 survivors treated between 2002 
and 2008 and screened using echocardiography, reported a 32% 
risk of asymptomatic valvular disorders after median follow-
up of 70.5 months (15). The odds ratio for a left-sided valvular 
defect in patients where more than 25% of the left ventricle 
received more than 30 Gy vs patients where 25% or less received 
more than 30 Gy was 4.4 (P = .02), but a dose-response relation-
ship could not be estimated because of the limited number of 
cases (n = 18). Most VHD cases were mild, and none was severe. 
After further follow-up, normal tissue complication models 
were fitted to the data from the cohort (27). The risk of valvular 
defects increased with maximum heart dose, while the risk of 
left-sided defects increased with the volume of the left cardiac 
chambers receiving 30 Gy or more. This is again consistent with 
our study.
The third study of 143 HL survivors treated between 1978 
and 1985 reported that 42% had VHD after a median follow-
up of 24  years (16). This high prevalence may be because the 
mid-mediastinal dose was high (40.3 Gy) and all individuals 
underwent screening with cardiac magnetic resonance imaging, 
Table 2. Distribution of case patients and control patients who were initially selected for the case-control study by final study status*
Status within study
Case patients Control patients
No. (%) No. (%)
Initially selected 143 (100.0) 429 (100.0)
 Ineligible 43 (30.7) 27 (6.3)
  Prior cardiovascular diagnosis 15 (10.5) 7 (1.6)
  No VHD 7 (4.9) –
  Grade 1 VHD only 15 (10.5) –
  Medical record lost 3 (2.1) 4 (0.9)
  Lost to follow-up – 5 (1.2)
  Cutoff date changed – 7 (1.6)
  Other reason 3 (2.1) 4 (0.9)
 Selected as control, case excluded 129 (30.1)
 Selected as third control, not used 55 (12.8)
 Administrative reasons for exclusion 11 (7.7) 18 (4.2)
  Case unconfirmed 8 (5.6) 15 (3.5)
  Case without controls 3 (2.1) –
  Control not abstracted – 2 (0.5)
  Control abreacted twice – 1 (0.2)
Total excluded 54 (37.8) 229 (53.4)
Total included in study 89 (62.2) 200 (46.6)
Duplicate controls 43 (21.5)
 Case as control 13 (6.5)
  Once 12 (6)
  Twice 1 (0.5)
 Control as control 24 (12)
  Once 20 (10)
  Twice 3 (1.5)
  Three times 1 (0.5)
Total number of unique individuals in study 89 (100.0) 157 (78.5)
* VHD = valvular heart disease.
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which detected many asymptomatic defects. No association 
was observed between doses to specific cardiac structures and 
cardiac pathologies, perhaps because of the narrow dose range 
(16). In contrast, our cohort had no systematic screening for car-
diac effects, considered only VHD as a first cardiac diagnosis, 
and had a greater proportion of higher-grade VHD.
Radiation-related VHD has been reported following child-
hood cancer, with statistically significant increases following 
mean cardiac doses of 15–34 Gy and 35 Gy (28) or more, and also 
in breast cancer (29). Taken together, all these studies suggest 
that cardiac doses of 30 Gy or more increase VHD risk, while at 
lower doses the increase per Gy is smaller and there may be a 
threshold dose below which there is no risk.
The use of a substitute CT dataset to derive retrospective 
dose estimates is a limitation of our study. The substitute CT 
datasets were chosen to be anatomically and dosimetrically 
typical, so that our dose estimates are near to the average of the 
true values. Inter-patient variability in anatomy, particularly 
cardiac size, shape, and position, could not be accounted for 
but is likely to be only a minor source of variation, as the heart 
valves are within the centre of the field and generally not close 
to lung shielding. Further uncertainties include the lack of 
original planning and/or verification films for a proportion of 
patients. Quantitative estimates of the dosimetric uncertain-
ties are not available, rendering it impossible to quantify their 
effects on our estimates of VHD risk, but it is unlikely to be 
substantial.
Splenectomy was the only other treatment factor inde-
pendently associated with an increase in VHD. There may be 
infectious, immune-related or inflammatory effects of sple-
nectomy that increase the risk of VHD. The aetiology of VHD 
is incompletely understood, but it is now recognized that, like 
atherosclerosis, inflammation may play a role (30). Elsewhere, 
the association between splenectomy and subsequent VHD has 
been reported to be statistically nonsignificant (12). Splenectomy 
is no longer routinely used for the staging and treatment of HL. 
Table 3. Patient-related cardiovascular risk factors in five-year survivors of Hodgkin lymphoma (HL) who were subsequently diagnosed with 
valvular heart disease (VHD) as their first cardiac diagnosis (case patients) and in those with no diagnosis of cardiac disease (control patients), 
and association between these factors and the rate of development of VHD
Patient-related factor Case patients/ Control patients  RR* (95% CI) P RR with additional adjustment† (95% CI) P
Obesity at HL diagnosis
 No‡ 60/160 1.0 1.0
 Yes 27/36 2.1 (1.1 to 3.8) .02 2.0 (1.0 to 4.0) .05
 Unknown 2/4 -
Obesity at end of FU
 No‡ 55/124 1.0 1.0
 Yes 31/58 1.2 (0.7 to 2.1) .60 0.8 (0.4 to 1.6) .62
 Unknown 3/18 - -
Smoker at HL diagnosis
 No‡ 44/96 1.0 1.0
 Yes 40/101 0.8 (0.5 to 1.4) .40 0.9 (0.5 to 1.7) .81
 Unknown 5/3 - -
Smoker at end of FU
 No‡ 73/146 1.0 1.0
 Yes 12/33 0.7 (0.3 to 1.5) .40 0.6 (0.2 to 1.5) .28
 Unknown 4/21 - -
Diabetes at end of FU
 No‡ 78/170 1.0 1.0
 Yes 11/23 1.1 (0.5 to 2.5) .76 1.2 (0.5 to 2.9) .65
 Unknown 0/7 - -
Hypertension at end of FU
 No‡ 58/152 1.0 1.0
 Yes 31/43 2.0 (1.1 to 3.5) .02 1.3 (0.7 to 2.6) .39
 Unknown 0/5 - -
Hypercholesterolaemia at end of FU
 No‡ 49/168 1.0 1.0
 Yes 40/26 4.9 (2.6 to 9.1) <.001 5.0 (2.6 to 9.5) <.001
 Unknown 0/6 - -
Number of factors
 0 12/38 1.0 (0.5 to 1.9) -
 1 28/86 1.0 (0.7 to 1.6) -
 2 25/52 1.5 (0.9 to 2.4) -
 3 17/19 3.1 (1.5 to 6.3) -
 4/5 7/5 3.7 (1.2 to 11.5) .002§ - -
* Rate ratios for the rate of development of valvular heart disease calculated conditional on matched sets. Matching variables were gender, age at HL diagnosis and 
date of HL diagnosis (Supplementary Table 2, available online). CI = confidence interval; FU = follow-up.
† Additional adjustments were: hypercholesterolaemia at end of FU for obesity at HL diagnosis, obesity at HL diagnosis for hypercholesterolaemia at end of FU, and 
both obesity at HL diagnosis and hypercholesterolaemia at end of FU for other factors.
‡ Reference category.
§ Ptrend (all other tests are for heterogeneity). All statistical tests were two-sided.
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However the effect, if real, could be of relevance to HL survivors 
given a splenectomy.
Anthracyclines are known to cause cardiomyopathy and 
congestive cardiac failure (31). An earlier analysis of this cohort 
reported that anthracyclines increased the risk of VHD from medi-
astinal radiotherapy (hazard ratio [HR] = 2.1, 95% CI = 1.3 to 3.5) 
(2). In the present analysis, there was no statistically significant 
association, although the 95% confidence interval for an effect of 
anthracycline exposure was wide (0.3 to 4.3) (Table 4). A possible 
explanation for this apparent inconsistency is that the present 
analysis considered only case patients whose first clinically sig-
nificant heart disease was VHD, while the earlier one included 
all diagnoses of VHD including those following ischaemic heart 
disease or cardiomyopathy. The effect of anthracyclines with 
or without RT on VHD has not been extensively investigated in 
other studies, but an increased risk of hospitalization for cardiac 
disease following treatment with doxorubicin-containing chemo-
therapy and RT vs chemotherapy alone has been reported (6).
Neither vincristine nor procarbazine chemotherapy were 
found to be independent risk factors for VHD. Exposure to vinca 
alkaloids has previously been associated with an increased risk 
of death from myocardial infarction following treatment for HL 
(7), but vincristine has never been associated with VHD or any 
other cardiac diseases.
Table 4. Treatment-related factors in five-year survivors of Hodgkin lymphoma (HL) who were subsequently diagnosed with valvular heart 
disease (VHD) as a first cardiac diagnosis (case patients) and in those with no diagnosis of cardiac disease (control patients), and association 
between these factors and the rate of development of VHD
Treatment-related factor Case patients/ Control patients RR* (95% CI) P RR with additional adjustment† (95% CI) P
Treatment centre
 NKI-AVL 35/85 1.0 (0.7 to 1.5) -
 DdHK 37/81 1.2 (0.8 to 1.8) -
 LUMC 17/34 1.2 (0.7 to 2.2) .83 - -
Prescribed mediastinal radiation dose (EQD2)
 No mediastinal RT 3/28 1.0 (0.3 to 3.3) 1.0 (0.3 to 3.5)
 ≤30 Gy (median 25.2 Gy) 2/11 0.7 (0.1 to 5.6) 0.6 (0.1 to 4.7)
 31–35 Gy (median 35.0 Gy) 17/41 3.4 (2.0 to 6.1) 3.1 (1.7 to 5.7)
 36–40 Gy (median 40.0 Gy) 58/109 4.5 (3.2 to 6.2) 4.1 (2.9 to 5.6)
 >40 Gy (median 42.0 Gy) 3/8 3.9 (1.0 to 14.7) .003§ 4.6 (1.2 to 18.5) .005§
 Unknown 6/3 -
Estimated radiation dose to affected valve (EQD2)
 No mediastinal RT 2/18 1.0 (0.2 to 4.9) 1.0 (0.2 to 4.8)
 ≤30 Gy (median 22.9 Gy) 5/33 1.5 (0.5 to 3.9) 1.4 (0.5 to 3.8)
 31–35 Gy (median 34.0 Gy) 16/51 3.4 (1.9 to 6.0) 3.1 (1.7 to 5.6)
 36–40 Gy (median 38.8 Gy) 45/82 5.5 (4.0 to 7.7) 5.4 (3.9 to 7.7)
 >40 Gy (median 42.2 Gy) 15/13 12.1 (5.1 to 28.9) <.001§ 11.8 (4.9 to 28.5) <.001§
 Unknown 6/3 -
Any chemotherapy
 No‡ 49/71 1.0 1.0
 Yes 40/129 0.7 (0.4 to 1.1) .12 1.3 (0.7 to 2.5) .38
Anthracycline
 No‡ 74/173 1.0 1.0
 Yes 15/27 1.4 (0.5 to 3.7) .55 1.2 (0.3 to 4.3) .79
Vincristine
 No‡ 62/105 1.0 1.0
 Yes 27/95 0.4 (0.2 to 0.7) .003 0.6 (0.3 to 1.1) .11
Procarbazine
 No‡ 59/104 1.0 1.0
 Yes 30/96 0.5 (0.3 to 0.9) .02 0.7 (0.3 to 1.4) .28
Splenectomy after HL diagnosis
 No‡ 45/133 1.0 1.0
 Yes 44/67 2.3 (1.3 to 4.3) .007 2.3 (1.1 to 4.5) .02
Any salvage treatment for HL
 No‡ 69/152 1.0 -
 Yes 20/47 0.9 (0.5 to 1.6) .72 - -
 Unknown 0/1 -
Any invasive second cancer
 No‡ 53/132 1.0 -
 Yes 36/68 1.4 (0.8 to 2.4) .21 - -
* Rate ratios for the rate of development of valvular heart disease calculated conditional on matched sets. Matching variables were sex, age at HL diagnosis, and date 
of HL diagnosis (Supplementary Table 2, available online). CI = confidence interval; DdHK = The Erasmus MC-Daniel den Hoed Cancer Center; LUMC = Leiden Univer-
sity Medical Center; NKI-AVL = The Netherlands Cancer Institute, Amsterdam; RR = rate ratio; RT = Radiotherapy; EQD2 = Equivalent dose in 2 Gy fractions.
† Additional adjustments were: splenectomy and any chemotherapy for radiation dose, radiation dose to the affected valve and splenectomy for any chemotherapy, 
radiation dose to affected valve and any chemotherapy for splenectomy, radiation dose to the affected valve, and splenectomy for other variables.
‡ Reference category.
§ Ptrend (all other tests for heterogeneity). All statistical tests were two-sided.
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/article-abstract/107/4/djv008/894367 by Erasm
us U
niversity R
otterdam
 user on 28 August 2019
Cutter et al. | 8 of 9
a
r
t
ic
le
Hypertension and hypercholesterolaemia at the end of fol-
low-up were both associated with an increase in VHD, as were 
an increasing number of cardiac risk factors in total (Table 3). 
However, it is not possible to conclude that these associations 
are causal as patients with known VHD (including grade 1 VHD) 
are likely to be closely monitored for cardiac risk factors and 
the risk factors for VHD and atherosclerosis are similar (32). 
Nevertheless, these findings highlight the need to monitor and 
treat HL patients for conventional cardiovascular risk factors, 
as they are also at increased risk of coronary artery disease (2).
Obesity at diagnosis, but not at the end of follow-up, was also 
associated with VHD risk, but again the association may not be 
causal as mediastinal separation is greater in obese patients, 
possibly leading to increased inhomogeneity in radiation dose 
and to areas of increased dose to the heart valves. This dosi-
metric effect would not have been accounted for by our dose 
reconstruction methods.
This study confirms that radiation dose to the heart valves 
is the main risk factor for the development of clinically signifi-
cant VHD following treatment for HL. It is the first time that a 
dose-response relationship has been derived in terms that can 
be easily translated into clinical practice. It will help clinicians 
assess the risk of VHD for patients treated in the future and 
will assist in guiding the appropriate follow-up of HL survivors.
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